## Answer
(model generated chain of thought explanation)

Given the patient's symptoms and laboratory findings, we can deduce that she likely has a condition known as Multiple Endocrine Neoplasia Type 2B (MEN2B). This condition is characterized by the presence of medullary thyroid carcinoma, pheochromocytoma, and primary hyperparathyroidism.

The patient's history of recurrent antral and duodenal peptic ulcers, as well as her treatment for a prolactinoma 5 years ago, suggests that she may have a MEN2A syndrome. However, the presence of multiple kidney stones in the left ureteropelvic junction is more typical of MEN2B.

The elevated parathyroid hormone (PTH) level of 826 pg/mL further supports the diagnosis of primary hyperparathyroidism, which is a hallmark of MEN2B.

Regarding the protein abnormalities listed:

A. Inactivation of RET proto-oncogene: This is associated with Multiple Endocrine Neoplasia Type 2A (MEN2A), not MEN2B.

B. Altered merlin protein expression: Merlin is a tumor suppressor gene that encodes for a protein involved in the Wnt signaling pathway. Mutations in this gene are associated with MEN2A, but not MEN2B.

C. Altered menin protein: Menin is another tumor suppressor gene that encodes for a protein involved in the Wnt signaling pathway. Mutations in this gene are also associated with MEN2A, but not MEN2B.

D. Mutation in C-Kit protein: The C-Kit gene encodes for a receptor tyrosine kinase involved in cell growth and division. A mutation in the C-Kit gene is associated with gastrointestinal stromal tumors (GISTs), which are more commonly found in patients with MEN2A, but not typically MEN2B.

Therefore, given the patient's presentation of primary hyperparathyroidism, multiple kidney stones, and a history of peptic ulcers, the most likely protein abnormality is related to the RET proto-oncogene.